Arcus Biosciences (RCUS) has been in focus after first quarter 2026 results, which showed revenue of US$17 million and a net loss of US$128 million, alongside several pipeline and collaboration setbacks.

The share price has been volatile around the recent Q1 2026 update and pipeline news. The 1 month share price return is 12.28% and the 90 day share price return is 17.83%, while the 1 year total shareholder return of 190.50% contrasts with a weaker 5 year total shareholder return of a 10.38% decline. This suggests that momentum has been strong recently but not consistently over a longer horizon.

If you are comparing Arcus Biosciences with other cancer and immunotherapy developers, it can help to widen the lens and scan 35 healthcare AI stocks

With earnings under pressure, pipeline setbacks and the stock still trading below the average analyst price target, the key question is whether Arcus is now undervalued or if the market is already factoring in its future prospects.

Most Popular Narrative: 27.1% Undervalued

Against the last close of $24.78, the most followed narrative pins Arcus Biosciences' fair value at $34.00, framing the recent volatility in a very different light.

Arcus Biosciences is prioritizing the launch of its late-stage development program for the HIF-2 alpha inhibitor, casdatifan, which has shown significant efficacy differentiation relative to existing market competitors. This could enhance future revenue through competitive advantage in the RCC market.

Curious what kind of revenue path and margin shift could support that gap between fair value and today’s price? The narrative leans on aggressive top line expectations and a future profitability profile that looks very different to Arcus' current loss making position. It also applies a valuation multiple more often associated with mature leaders than clinical stage biotechs. The full breakdown shows exactly how those ingredients combine into a $34.00 fair value call.

Result: Fair Value of $34 (UNDERVALUED)

However, investors still face real downside risk if key casdatifan or domvanalimab trials disappoint, or if regulatory delays and safety concerns weaken the kidney cancer thesis.

Another Angle on Valuation

The narrative fair value of $34.00 paints Arcus as 27.1% undervalued, but the price to sales picture is tougher. At a P/S of 13.2x, the stock trades above the US Biotechs industry at 10.9x and well above a fair ratio of 0.9x, which points to meaningful valuation risk if sentiment cools.

Our valuation breakdown walks through how these ratios stack up against peers and what would need to change in revenue, margins and sentiment for the market to move closer to that fair ratio, so you can judge whether the current premium feels justified or stretched See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between recent share price strength and fundamental questions, this is a moment to look closely at the data and move decisively by weighing the stock's 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better fit your goals, risk comfort and time horizon, so keep widening your search.

• Target potential mispricings by scanning 51 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their qualities.
• Strengthen your income focus by reviewing 12 dividend fortresses offering yields of 5% or more, alongside a focus on stability.
• Prioritise resilience by checking 72 resilient stocks with low risk scores that screen well on financial health and overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.